// App-Quantinova.ai

e18194 : Recognition of tumor lysis syndrome (TLS) risk and appropriateness of prophylaxis before and after adoption of a web broswer based risk assessment tool.

Researchers

Presenter

  • Jean Kerins

Principal Investigators

  • Roisin O Sullivan

  • Kate Murphy

  • Gul Ahmed

  • Raimundas Galiauskas

  • Brian Richard Bird

  • Conleth G. Murphy

Medical Centers

  • Bon Secours Hospital, Cork, Ireland

Locations

  • Ireland

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Hematological malignancies

  • Solid malignancies

  • Tumor lysis syndrome

  • Lymphomas

Biomarkers

  • RNA-binding protein FUS/TLS

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Multinational

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved